MARKET NEWS

 

Imbria Presents Positive Clinical Data for Ninerafaxstat From IMPROVE-DiCE
Esperion Announces Bempedoic Acid Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of its Dual-Acting Factor XI Inhibitor
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in General Anxiety Disorder 
Daré Bioscience Announces Global Licensing Rights to Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
Immatics Announces First Cancer Patient Treated With Second-Generation ACTengine TCR-T Candidate

  FEATURED EDITORIAL

  COMPANY PROFILE

Evonik Health Care is a global innovation hub for the world’s leading life science companies. We support customers along the entire product cycle from early development to commercial manufacturing. Our system solutions are backed by the scientific excellence of our interdisciplinary and diverse teams. As an integrated CDMO, Evonik Health Care has been a leader for advanced drug delivery for many decades. It is also one of the world’s largest contract manufacturers of high potency APIs (HPAPIs) and active pharmaceutical ingredients (APIs) that require complex chemistry and multiple-step syntheses. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy

Timber Pharmaceuticals, Inc. recently announced that results from the previously completed Phase 2b CONTROL study that evaluated TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in moderate-to-severe congenital ichthyosis (CI) are published….

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of First-in-Class BRD4-Targeting CHAMP Protein Degrader

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of First-in-Class BRD4-Targeting CHAMP Protein Degrader

Ranok Therapeutics recently announced the initiation of patient dosing in the US for a Phase 1/2 study of RNK05047. The trial, entitled CHAMP-1, will evaluate the safety, tolerability, pharmacokinetics, and….

Zerion Pharma & Hovione Extend Partnership to Cover Use of Dispersome Technology Platform in Nutraceuticals

Zerion Pharma & Hovione Extend Partnership to Cover Use of Dispersome Technology Platform in Nutraceuticals

Hovione and Zerion Pharma A/S (Zerion) recently announced an extension of their collaboration on Zerion’s Dispersome technology into the nutraceutical/dietary….

Oculis Announces Phase 2 Data Showing Topical Eye Drops Anti-TNFα Agent Licaminlimab Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease

Oculis Announces Phase 2 Data Showing Topical Eye Drops Anti-TNFα Agent Licaminlimab Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease

Oculis S.A. recently announced results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe….

  WHITEPAPERS & WEBINARS

WEBINAR - Getting to the Core of Pellet Coating

WEBINAR - Getting to the Core of Pellet Coating

This webinar is part of The future of solid dosage, an ACG 360 webinar series covering wide-ranging, simple, and transformative ways to achieve smarter pharma formulation, manufacture, and packaging.

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.

Download our whitepaper and learn …

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mecha­nisms of action continue to drive drug candidates’ phys­ical properties toward …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 7 – Lyophilization Manufacturing
September 14 – Excipients